Mechanisms of resistance to antiangiogenesis therapy

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1323-1332

  Azam, Faisal ^a   Mehta, Shaveta ^a   Harris, Adrian L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR 2; GLYCOPROTEIN P; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IRINOTECAN; MONOCLONAL ANTIBODY DC101; NOTCH RECEPTOR; PACLITAXEL; PAZOPANIB; PLACENTAL GROWTH FACTOR; PROTEIN P53; SEMAXANIB; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; GH2 PROTEIN, HUMAN; GROWTH HORMONE; PLACENTAL PEPTIDE HORMONE;

ARTICLE; ASTROCYTOMA; BONE MARROW CELL; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; ENDOTHELIUM CELL; HORMESIS; HUMAN; HYPOXIA; NONHUMAN; OVARY CANCER; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; METABOLISM; NEOPLASM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CELL HYPOXIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GROWTH HORMONE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLACENTAL HORMONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951667987     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.020     Document Type: Article

References (120)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Baeriswyl V., and Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol (2009)
3. Italiano Jr. J.E., Richardson J.L., Patel-Hett S., et al. Angiogenesis is regulated by a novel mechanism: pro- and anti-angiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111 (2008) 1227-1233
4. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
5. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
6. Schmidt C. Why do tumors become resistant to antiangiogenesis drugs?. J Natl Cancer Inst (2009)
7. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8 (2008) 579-591
8. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
9. Burris III H., and Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13 (2008) 289-298
10. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008) 592-603
11. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
12. Shojaei F., and Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 11 (2008) 219-230
13. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
14. Escudier B.S.C., Eisen T., et al. Randomized phase III trial of Raf kinase and VEGFR inhibitor in patients with advanced renal cell cancer. J Clin Oncol 23 (2005) 15-16
15. Smith J.K., Mamoon N.M., and Duhe R.J. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14 (2004) 175-225
16. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 (2005) 328-335
17. Ellis L.M., and Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14 (2008) 6371-6375
18. Shojaei F., and Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 13 (2007) 345-348
19. Miller K.D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3 (2003) 421-422
20. Grunewald M., Avraham I., Dor Y., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
21. Zwaans B.M., and Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 74 (2007) 145-158
22. Fischer C., Mazzone M., Jonckx B., and Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 8 (2008) 942-956
23. Neufeld G., Kessler O., and Herzog Y. The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 515 (2002) 81-90
24. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
25. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006;9:225-30 [discussion 31].
26. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104 (2007) 17069-17074
27. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2009.
28. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (2004) 507-516
29. Noguera-Troise I., Daly C., Papadopoulos N.J., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444 (2006) 1032-1037
30. Williams C.K., Li J.L., Murga M., Harris A.L., and Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107 (2006) 931-939
31. Shawber C.J., Funahashi Y., Francisco E., et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 117 (2007) 3369-3382
32. MacKenzie F., Duriez P., Wong F., Noseda M., and Karsan A. Notch4 inhibits endothelial apoptosis via RBP-Jkappa-dependent and -independent pathways. J Biol Chem 279 (2004) 11657-11663
33. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5 (2004) 816-826
34. Byzova T.V., Goldman C.K., Pampori N., et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 6 (2000) 851-860
35. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
36. Adini A., Kornaga T., Firoozbakht F., and Benjamin L.E. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62 (2002) 2749-2752
37. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9 (2003) 936-943
38. Marcellini M., De Luca N., Riccioni T., et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 169 (2006) 643-654
39. Taylor A.P., and Goldenberg D.M. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 6 (2007) 524-531
40. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007) 463-475
41. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99 (2002) 11393-11398
42. Nguyen Q.D., Shah S.M., Browning D.J., et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116 (2009) 2141-2148 e1
43. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25 (2007) 911-920
44. Kawamura H., Li X., Harper S.J., Bates D.O., and Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 68 (2008) 4683-4692
45. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
46. Varey A.H., Rennel E.S., Qiu Y., et al. VEGF 165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and anti-angiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98 (2008) 1366-1379
47. Rennel E., Waine E., Guan H., et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 98 (2008) 1250-1257
48. Bates D.O., Cui T.G., Doughty J.M., et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62 (2002) 4123-4131
49. Cebe Suarez S., Pieren M., Cariolato L., et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 63 (2006) 2067-2077
50. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6 (2009) 327-338
51. Masago K., Fujita S., Kim Y.H., et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 100 (2009) 1917-1922
52. Guan X., Zhao H., Niu J., Tang D., Ajani J.A., and Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 9 (2009) 77
53. Smerdel M.P., Waldstrom M., Brandslund I., Steffensen K.D., Andersen R.F., and Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 19 (2009) 578-584
54. Schneider B.P., Radovich M., Sledge G.W., et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111 (2008) 157-163
55. Pander J., Gelderblom H., and Guchelaar H.J. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 12 (2007) 1054-1060
56. Kataoka N., Cai Q., Wen W., et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15 (2006) 1148-1152
57. Sfar S., Saad H., Mosbah F., and Chouchane L. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol Biol Rep 36 (2009) 37-45
58. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26 (2008) 4672-4678
59. Schultheis A.M., Lurje G., Rhodes K.E., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14 (2008) 7554-7563
60. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
61. Semenza G.L. Hypoxia and cancer. Cancer Metastasis Rev 26 (2007) 223-224
62. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
63. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
64. Bos R., van der Groep P., Greijer A.E., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
65. Sathornsumetee S., Cao Y., Marcello J.E., et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26 (2008) 271-278
66. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
67. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
68. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (2006) 2610-2621
69. Liang W.C., Wu X., Peale F.V., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281 (2006) 951-961
70. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
71. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
72. Nozawa H., Chiu C., and Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103 (2006) 12493-12498
73. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9 (2009) 239-252
74. De Palma M., Venneri M.A., Galli R., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
75. Hattori K., Heissig B., Wu Y., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8 (2002) 841-849
76. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
77. Du R., Lu K.V., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
78. Eikesdal H.P., Sugimoto H., Birrane G., et al. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci USA 105 (2008) 15040-15045
79. Gupta G.P., and Massague J. Cancer metastasis: building a framework. Cell 127 (2006) 679-695
80. Shojaei F., Singh M., Thompson J.D., and Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 105 (2008) 2640-2645
81. Marigo I., Dolcetti L., Serafini P., Zanovello P., and Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222 (2008) 162-179
82. Shojaei F., Wu X., Qu X., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 106 (2009) 6742-6747
83. Pham N.A., Schwock J., Iakovlev V., Pond G., Hedley D.W., and Tsao M.S. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer 8 (2008) 43
84. Faivre S., Djelloul S., and Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33 (2006) 407-420
85. Cao R., Brakenhielm E., Pawliuk R., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9 (2003) 604-613
86. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
87. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
88. Sainson R.C., and Harris A.L. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 11 (2008) 41-51
89. Thurston G., Noguera-Troise I., and Yancopoulos G.D. The delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7 (2007) 327-331
90. Ridgway J., Zhang G., Wu Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444 (2006) 1083-1087
91. Yan M., and Plowman G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 13 (2007) 7243-7246
92. Diez H., Fischer A., Winkler A., et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res 313 (2007) 1-9
93. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
94. Pietras K., Pahler J., Bergers G., and Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5 (2008) e19
95. Jechlinger M., Sommer A., Moriggl R., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116 (2006) 1561-1570
96. Greenberg J.I., Shields D.J., Barillas S.G., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456 (2008) 809-813
97. Xian X., Hakansson J., Stahlberg A., et al. Pericytes limit tumor cell metastasis. J Clin Invest 116 (2006) 642-651
98. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
99. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
100. Hariharan S., Gustafson D., Holden S., et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18 (2007) 1400-1407
101. Calabrese E.J. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 35 (2005) 463-582
102. Reynolds A.R., Hart I.R., Watson A.R., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15 (2009) 392-400
103. Dome B., Paku S., Somlai B., and Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 197 (2002) 355-362
104. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
105. Leenders W.P., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10 (2004) 6222-6230
106. Hillen F., and Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26 (2007) 489-502
107. Teodoro J.G., Evans S.K., and Green M.R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 85 (2007) 1175-1186
108. Gaiser T., Becker M.R., Meyer J., Habel A., and Siegelin M.D. P53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem Int 54 (2009) 458-463
109. Giuriato S., Ryeom S., Fan A.C., et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 103 (2006) 16266-16271
110. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002) 1526-1528
111. Brendel C., Scharenberg C., Dohse M., et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21 (2007) 1267-1275
112. Shukla S., Robey R.W., Bates S.E., and Ambudkar S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37 (2009) 359-365
113. Hida K., Hida Y., Amin D.N., et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64 (2004) 8249-8255
114. Xiong Y.Q., Sun H.C., Zhang W., et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15 (2009) 4838-4846
115. Ebos J.M., Lee C.R., and Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15 (2009) 5020-5025
116. Blouw B., Song H., Tihan T., et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
117. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
118. Narayana A., Kelly P., Golfinos J., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110 (2009) 173-180
119. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
120. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799